Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shawnte Mitchell Sells 15,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Shawnte Mitchell sold 15,000 shares of Olema Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $23.01, for a total transaction of $345,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shawnte Mitchell also recently made the following trade(s):

• On Wednesday, March 4th, Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00.

Olema Pharmaceuticals Stock Down 3.6%

Olema Pharmaceuticals stock traded down $0.81 during mid-day trading on Friday, hitting $21.75. 263,409 shares of the company’s stock were exchanged, compared to its average volume of 1,275,949. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $36.26. The stock has a 50 day moving average of $25.25 and a two-hundred day moving average of $17.95. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.49 billion, a P/E ratio of -11.63 and a beta of 1.92.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds have recently modified their holdings of OLMA. Ameritas Investment Partners Inc. increased its position in Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares during the period. EverSource Wealth Advisors LLC grew its position in Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares during the last quarter. Torren Management LLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter worth about $44,000. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals during the 3rd quarter worth about $53,000. Finally, American Century Companies Inc. acquired a new position in shares of Olema Pharmaceuticals during the second quarter valued at about $54,000. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Oppenheimer boosted their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. The Goldman Sachs Group boosted their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Piper Sandler began coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Citigroup lifted their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.